Novo Nordisk Announces €2.1 Billion Investment in New Manufacturing Facility in France
Novo Nordisk has confirmed a €2.1 billion investment to establish a new manufacturing facility in Chartres, France. The site will focus on producing treatments for chronic diseases such as diabetes and obesity, and is expected to create around 500 jobs. The facility is planned to be operational by 2028, expanding Novo Nordisk's manufacturing footpr...
- Published date: 19-07-2026 10:01 AM
Novo Nordisk has announced a €2.1 billion investment to build a new manufacturing facility in Chartres, France. The facility will focus on producing treatments for serious chronic diseases, including diabetes and obesity.
This expansion is expected to create approximately 500 new jobs and strengthen Novo Nordisk's production capacity in Europe. The company stated that the investment reflects its commitment to meeting the growing global demand for innovative therapies.
The new site will be integrated with Novo Nordisk's existing operations in Chartres and is scheduled to be operational by 2028. For more details, visit the official Novo Nordisk announcement.
Novo Nordisk has confirmed a €2.1 billion investment to establish a new manufacturing facility in Chartres, France. The site will focus on producing treatments for chronic diseases such as diabetes and obesity, and is expected to create around 500 jobs. The facility is planned to be operational by 2028, expanding Novo Nordisk's manufacturing footprint in Europe.